Improved disease-free survival with adjuvant radiotherapy in early-stage endometrial cancer: 10-year outcome analysis

Suheyla Arslan; Gulhan Avcı; Ebru Akkas; Yıldız Guney

doi:10.5114/jcb.2020.101690

eISSN: 2081-2841
ISSN: 1689-832X

Journal of Contemporary Brachytherapy

Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links

Editorial System

Submit your Manuscript

6/2020
vol. 12

Send email

Copy url:

abstract:

Original paper

Improved disease-free survival with adjuvant radiotherapy in early-stage endometrial cancer: 10-year outcome analysis

Suheyla Aytac Arslan

¹

,

Gulhan Guler Avcı

²

,

Ebru Atasever Akkas

³

,

Yıldız Guney

⁴

Department of Radiation Oncology, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey
Department of Radiation Oncology, Faculty of Medicine, Gaziosmanpaşa University, Tokat, Turkey
Department of Radiation Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
Department of Radiation Oncology, Ankara Memorial Hospital, Ankara, Turkey

J Contemp Brachytherapy 2020; 12, 6: 572–578

DOI: https://doi.org/10.5114/jcb.2020.101690

Online publish date: 2020/12/18

View full text Get citation

Purpose
The purpose of this study was to evaluate long-term treatment outcomes and prognostic factors affecting survival of patients with early-stage endometrial carcinoma.

Material and methods
Data of 311 patients with FIGO stage I-II endometrial cancer, curatively treated at two different tertiary centers between June 2001 and December 2016 were retrospectively reviewed. The patients had primary surgery, 74 (24%) received no further treatment, 4 (1%) obtained chemotherapy only, 234 (75%) received radiotherapy, and 24 (7%) received both.

Results
Median follow-up time was 102 (range, 3-205) months. During this period, 68 (21.9%) patients died. 5-year and 10-year disease-free survival (DFS) were 76% and 74.3%, respectively. In multivariate analysis, lower uterine segment invasion positivity and no adjuvant radiotherapy were determined as independent unfavorable prognostic factors for DFS. The 5-year and 10-year disease-specific survival (DSS) were 86.8% and 82.2%, respectively. For DSS, high-grade, lymphovascular space invasion positivity, stage II, ≥ 65 age, and no adjuvant radiotherapy were found to be independent unfavorable prognostic markers.

Conclusions
The findings of our cohort have confirmed the importance of adjuvant radiotherapy on long-term early-stage endometrial carcinoma outcome.

keywords:

Improved disease-free survival with adjuvant radiotherapy in early-stage endometrial cancer: 10-year outcome analysis

Suheyla Aytac Arslan 1 , Gulhan Guler Avcı 2 , Ebru Atasever Akkas 3 , Yıldız Guney 4

early-stage endometrium cancer, adjuvant therapy, radiotherapy, survival

Suheyla Aytac Arslan

¹

,

Gulhan Guler Avcı

²

,

Ebru Atasever Akkas

³

,

Yıldız Guney

⁴